Table 1.
Essential characteristics of the studies included in the meta-analysis.
| Author | Year of publication | Design | No. pts | Tumor type | No. pts with SCC | RT Schedule | CT Schedule |
|---|---|---|---|---|---|---|---|
| Allum et al. (14) | 2009 | NCT-S vs. S | 802 | AC, SCC, undifferentiated carcinoma | 247 | NA | Two cycles of Cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2 daily as a continuous infusion over 96 h repeated every 3 weeks. |
| Ando et al. (15) | 1997 | S-ACT vs. S | 205 | SCC | 205 | NA | Two cycles of Cisplatin (70 mg/m2) and vindesine (3 mg/m2) on days 1 and 21. |
| Ando et al. (16) | 2011 | S-ACT vs. NCT-S | 330 | SCC | 330 | NA | Two cycles of cisplatin 80 mg/m2 on day 1; 5-fluorouracil 800 mg/m2 on days 1 through 5. |
| Ando et al. (17) | 2003 | S-ACT vs. S | 242 | SCC | 242 | NA | Two courses of cisplatin (80 mg/m2 day1) and fluorouracil (800 mg/m2 days 1–5) |
| Ancona et al. (18) | 2001 | NCT+S vs. S | 94 | SCC | 94 | NA | Two cycles of cisplatin (100 mg/m2) and 5-fluorouracil (1,000 mg/m2). Cisplatin day 1 and 21. 5-fluorouracil days 1–5 and 21–26. |
| Bonstra et al. (19) | 2011 | NCT-S vs. S | 169 | SCC | 169 | NA | Two to four cycles of cisplatin, at a dose of 80 mg on day 1, Etoposide, at a dose of 100 mg/m2 on day 1 and day 2, followed by etoposide 200 mg/m2 orally on days 3 and 5, repeated every 3 weeks. |
| Bosset et al. (20) | 1997 | NCRT-S vs. S | 282 | SCC | 282 | 37 Gy/3.7 Gy/10 f | Two cycles of Cisplatin, at a dose of 80 mg/m2, d1–3 |
| Burmeister et al. (21) | 2005 | NCRT-S vs. S | 256 | SCC, AC | 95 | 35 Gy/2.3 Gy/15 f | One cycle of 80 mg/m2 cisplatin on day 1, 800 mg/m2 fluorouracil on days 1–4 |
| Gignoux et al. (22) | 1987 | NRT-S vs. S | 208 | SCC | 208 | 33 Gy/3.3 Gy/10 f | NA |
| Law et al. (23) | 1997 | NCT-S vs. S | 147 | SCC | 147 | NA | Two cycles cisplatin 100 mg/m2 d1 + fluorouracil 500 mg/m2/day d1–5 |
| Lee et al. (24) | 2004 | NCRT+S vs. S | 101 | SCC | 101 | 45.6 Gy/1.2 Gy/38 f | Two cycles of cisplatin (60 mg/m2) on days 1 and 21 and 5-FU (1000 mg/m2) from days 2–5 |
| Lv et al. (25) | 2010 | NCRT+S vs. S+ACRT vs. S | 238 | SCC | 238 | 40 Gy/2 Gy/20 f | Two cycles of PTX (135 mg/m2 per day) and DDP (20 mg/m2 per day) on days 1–3 and 22–24 of radiotherapy. |
| Marittte et al. (26) | 2014 | NCRT+S vs. S | 195 | AC, SCC | 57 | 45 Gy/1.8 Gy/25 f | Two cycles of fluorouracil (FU) + cisplatin from days 1 to 5 and 29 to 33 |
| Nygaard et al. (27) | 1992 | S vs. NCT+S vs. NRT+S vs. NCRT+S | 186 | SCC | 186 | 35 Gy/1.75 Gy/20 f | Two cycles of cisplatin (20 mg/m2) and bleomycin (5 mg/m2). Cisplatin days 1–5. Bleomycin day 1 |
| Shapiro et al. (8) | 2015 | NCRT-S | 368 | AC, SCC, undifferentiated carcinoma |
84 | 41.4 Gy/1.8 Gy/23 f | Five cycles carboplatin AUC 2 mg/ml/min d1, 8, 15, 22, 29 + paclitaxel 50 mg/m2 d1, 8, 15, 22, 29 |
| von Dobeln et al. (28) | 2018 | NCRT-S vs. NCT-S | 181 | AC, SCC | 50 | 40 Gy/2 Gy/20 f | Three cycles cisplatin 100 mg/m2 d1 + fluorouracil 750 mg/m2/day, d1–5 |
| Xiao et al. (29) | 2003 | S-ART vs. S | 495 | SCC | 495 | 60 Gy/30 f, transpositional stomach:50 Gy/25 f |
NA |
| Yang et al. (6) | 2018 | NCRT-S vs. S | 451 | SCC | 451 | 40 Gy/2 Gy/20 f | Two cycles vinorelbine 25mg/m2 d1,8 + cisplatin 75mg/m2 d1 q3wks |
| Zieren et al. (30) | 1995 | S-ART vs. S | 68 | SCC | 68 | 55.8 Gy/1.8 Gy/31 f | NA |
NA, Not applicable.